Skip Navigation

Finding a Better Way to Treat and Manage Multiple Sclerosis

Neurosciences Institute’s multiple sclerosis center is recognized as a leader in research and treatment by the National Multiple Sclerosis Society. Our nationally known, fellowship-trained specialists work with industry sponsors and others to find better ways to treat and manage the symptoms of multiple sclerosis (MS).

With access to a large and diverse population of MS patients and review by a fast IRB process, studies can be enrolled and approved quickly at our center. This makes us an attractive location for industry-sponsored trials looking to quickly enrolling patients for much-needed treatments and innovative approaches.

We are currently enrolling the following studies:

  • FLUENT - A 12-month, prospective, multicenter, two-cohort, non-randomized, open-label study in adult patients with relapsing multiple sclerosis to investigate changes in immune phenotype biomarkers after treatment with 0.5 mg fingolimod (FTY720)
  • LEM-COG - A 24-month, prospective, observational study to evaluate neurocognitive function and safety in patients with relapsing multiple sclerosis who are initiating LEMTRADA® treatment in routine clinical practice